-Выявление факторов, препятствующих успешной HER-таргетной терапии при раке молочной железы и разработка противоопухолевого препарата, связывающего HER-лиганды

January 6, 2018 — December 31, 2022

Buzdin A.A. (PI)

Group for Genomic Regulation of Cell Signaling Systems

Grant, RSF

List of publications

  1. Sorokin M, Ignatev K, Barbara V, Vladimirova U, Muraveva A, Suntsova M, Gaifullin N, Vorotnikov I, Kamashev D, Bondarenko A, Baranova M, Poddubskaya E, Buzdin A (2020). Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels. Biochemistry (Mosc) 85 (7), 758–772
  2. Sorokin M, Ignatev K, Poddubskaya E, Vladimirova U, Gaifullin N, Lantsov D, Garazha A, Allina D, Suntsova M, Barbara V, Buzdin A (2020). RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. Biomedicines 8 (5),
  3. (book) Nikitin D, Sorokin M, Tkachev V, Garazha A, Markov A, Buzdin A (2019). RetroSpect, a new method of measuring gene regulatory evolution rates using co-mapping of genomic functional features with transposable elements. Evolution, Origin of Life, Concepts and Methods 42 (1), 85–111
  4. Borisov N, Sorokin M, Tkachev V, Garazha A, Buzdin A (2020). Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments. BMC Med Genomics 13 (Suppl 8), 111
  5. Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, Allina D, Suntsova M, Tkachev V, Garazha A, Sekacheva M, Buzdin A (2020). RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud 6 (2),
  6. Buzdin A, Skvortsova II, Li X, Wang Y (2021). Editorial: Next Generation Sequencing Based Diagnostic Approaches in Clinical Oncology. Front Oncol 10, 635555
  7. Kamashev D, Sorokin M, Kochergina I, Drobyshev A, Vladimirova U, Zolotovskaia M, Vorotnikov I, Shaban N, Raevskiy M, Kuzmin D, Buzdin A (2021). Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. Heliyon 7 (3), e06394
  8. Raevskiy M, Sorokin M, Vladimirova U, Suntsova M, Efimov V, Garazha A, Drobyshev A, Moisseev A, Rumiantsev P, Li X, Buzdin A (2021). EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers. Biochemistry (Mosc) 86 (11), 1477–1488
  9. Lebedev TD, Khabusheva ER, Mareeva SR, Ivanenko KA, Morozov AV, Spirin PV, Rubtsov PM, Snezhkina AV, Kudryavtseva AV, Sorokin MI, Buzdin AA, Prassolov VS (2022). Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem 298 (8), 102226
  10. Kamashev D, Shaban N, Suntsova M, Raevskiy M, Efimov V, Moisseev A, Sorokin M, Buzdin A (2022). Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. Biomedicines 10 (8),
  11. Buzdin A, Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N, Wang Y, Li X, Kar S, Hartmann C, Samii A, Giese A, Borisov N (2018). Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs. Semin Cancer Biol 53, 110–124
  12. Tkachev V, Sorokin M, Mescheryakov A, Simonov A, Garazha A, Buzdin A, Muchnik I, Borisov N (2019). FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier. Front Genet 9 (JAN), 717
  13. Zolotovskaia MA, Sorokin MI, Roumiantsev SA, Borisov NM, Buzdin AA (2019). Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. Front Oncol 8 (JAN), 658
  14. Zolotovskaia MA, Sorokin MI, Emelianova AA, Borisov NM, Kuzmin DV, Borger P, Garazha AV, Buzdin AA (2019). Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Front Pharmacol 10 (JAN), 1
  15. Nikitin D, Garazha A, Sorokin M, Penzar D, Tkachev V, Markov A, Gaifullin N, Borger P, Poltorak A, Buzdin A (2019). Retroelement-Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution. Cells 8 (2), 130
  16. Suntsova M, Gaifullin N, Allina D, Reshetun A, Li X, Mendeleeva L, Surin V, Sergeeva A, Spirin P, Prassolov V, Morgan A, Garazha A, Sorokin M, Buzdin A (2019). Atlas of RNA sequencing profiles for normal human tissues. Sci Data 6 (1), 36
  17. Borisov N, Buzdin A (2019). New Paradigm of Machine Learning (ML) in Personalized Oncology: Data Trimming for Squeezing More Biomarkers From Clinical Datasets. Front Oncol 9, 658
  18. Buzdin A, Sorokin M, Poddubskaya E, Borisov N (2019). High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology. Cancer Inform 18, 1176935119838844
  19. (book) Borisov N, Sorokin M, Garazha A, Buzdin A (2020). Quantitation of Molecular Pathway Activation Using RNA Sequencing Data. Methods Mol Biol 2063, 189–206
  20. (book) Zolotovskaia M, Sorokin M, Garazha A, Borisov N, Buzdin A (2020). Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods Mol Biol 2063, 207–234
  21. (book) Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A (2020). Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol Biol 2063, 235–255